No evidence for association of ataxia-telangiectasia mutated gene T2119C and C3161G amino acid substitution variants with risk of breast cancer

Breast Cancer Research

KumKum Khanna⁴  Georgia Chenevix-Trench⁴  Beth Newman¹  Graham G Giles³  Margaret RE McCredie⁵  Xiaoqing Chen⁴  John L Hopper²  Amanda B Spurdle⁴ 

[1] School of Public Health, Queensland University of Technology, Kelvin Grove, Queensland, Australia;Centre for Genetic Epidemiology, University of Melbourne, Victoria, Australia;Cancer Epidemiology Centre, The Cancer Council Victoria, Carlton, Victoria, Australia;Cancer and Cell Biology Division, The Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Queensland, Australia;Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand

关键词: variant;    breast cancer;    ataxia-telangiectasia mutated gene;   

Others  :  1118819
DOI  :  10.1186/bcr534

 received in 2002-06-05, accepted in 2002-07-31,  发布年份 2002

【 摘 要 】

Background

There is evidence that certain mutations in the double-strand break repair pathway ataxia-telangiectasia mutated gene act in a dominant-negative manner to increase the risk of breast cancer. There are also some reports to suggest that the amino acid substitution variants T2119C Ser707Pro and C3161G Pro1054Arg may be associated with breast cancer risk. We investigate the breast cancer risk associated with these two nonconservative amino acid substitution variants using a large Australian population-based case–control study.

Methods

The polymorphisms were genotyped in more than 1300 cases and 600 controls using 5' exonuclease assays. Case–control analyses and genotype distributions were compared by logistic regression.

Results

The 2119C variant was rare, occurring at frequencies of 1.4 and 1.3% in cases and controls, respectively (P = 0.8). There was no difference in genotype distribution between cases and controls (P = 0.8), and the TC genotype was not associated with increased risk of breast cancer (adjusted odds ratio = 1.08, 95% confidence interval = 0.59–1.97, P = 0.8). Similarly, the 3161G variant was no more common in cases than in controls (2.9% versus 2.2%, P = 0.2), there was no difference in genotype distribution between cases and controls (P = 0.1), and the CG genotype was not associated with an increased risk of breast cancer (adjusted odds ratio = 1.30, 95% confidence interval = 0.85–1.98, P = 0.2). This lack of evidence for an association persisted within groups defined by the family history of breast cancer or by age.

Conclusion

The 2119C and 3161G amino acid substitution variants are not associated with moderate or high risks of breast cancer in Australian women.

【 授权许可】

   
2002 Spurdle et al., licensee BioMed Central Ltd

【 参考文献 】

• [1]Kerr P, Ashworth A: New complexities for BRCA1 and BRCA2. Curr Biol 2001, 11:R668-R676.
• [2]Khanna K, Jackson SP: DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001, 27:247-254.
• [3]Swift M: Public health burden of cancer in ataxia-telangiectasia heterozygotes. J Natl Cancer Inst 2001, 93:84-85.
• [4]Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Marsh A, Chen X, Donn K, Cummings M, Nyholt D, Jenkins MA, Scott C, Pupo GM, Dork T, Bendix R, Kirk J, Tucker K, McCredie MR, Hopper JL, Sambrook J, Mann GJ, Khanna KK: Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 2002, 94:205-215.
• [5]Teraoka SN, Malone KE, Doody DR, Suter NM, Ostrander EA, Daling JR, Concannon P: Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history. Cancer 2001, 92:479-487.
• [6]Dork T, Bendix R, Bremer M, Rades D, Klopper K, Nicke M, Skawran B, Hector A, Yamini P, Steinmann D, Weise S, Stuhrmann M, Karstens JH: Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res 2001, 61:7608-7615.
• [7]Sommer SS, Buzin CH, Jung M, Zheng J, Liu Q, Jeong SJ, Moulds J, Nguyen VQ, Feng J, Bennett WP, Dritschilo A: Elevated frequency of ATM gene missense mutations in breast cancer relative to ethnically matched controls. Cancer Genet Cytogenet 2002, 134:25-32.
• [8]Larson GP, Zhang G, Ding S, Foldenauer K, Udar N, Gatti R, Neuberg D, Lunetta K, Ruckdeschel JC, Longmate J, Flanagan S, Krontiris TG: An allelic variant at the ATM locus is implicated in breast cancer susceptibility. Genet Test 1997, 1:165-170.
• [9]Hopper JL, Giles GG, McCredie MRE, Boyle P: Background, rationale and protocol for a case–control–family study of breast cancer. The Breast 1994, 3:79-86.
• [10]Hopper JL, Chenevix-Trench G, Jolley DJ, Dite GS, Jenkins MA, Venter DJ, McCredie MRE, Giles GG: Design and analysis issues in a population-based case–control–family study of the genetic epidemiology of breast cancer and the Co-operative Family Registry for Breast Cancer Studies (CFRBCS). J Natl Cancer Inst Monogr 1999, 26:95-100.
• [11]McCredie MR, Dite GS, Giles GG, Hopper JL: Breast cancer in Australian women under the age of 40. Cancer Causes Control 1998, 9:189-198.
• [12]Southey MC, Batten LE, McCredie MRE, Giles GG, Dite G, Hopper JL, Venter DJ: Estrogen receptor polymorphism at codon 325 and risk of breast cancer in women before age forty. J Natl Cancer Inst 1998, 90:532-536.
• [13]Spurdle AB, Hopper JL, Chen X, McCredie MR, Giles GG, Venter DJ, Southey MC, Chenevix-Trench G: The progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of breast cancer in Australian women. Cancer Epidemiol Biomarkers Prev 2002, 11:439-443.